Free Trial
NASDAQ:ADMA

ADMA Biologics Q1 2025 Earnings Report

ADMA Biologics logo
$23.52 +0.25 (+1.07%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$23.65 +0.13 (+0.55%)
As of 05/2/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics EPS Results

Actual EPS
N/A
Consensus EPS
$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

ADMA Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
$116.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

ADMA Biologics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

ADMA Biologics Earnings Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
See More ADMA Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ADMA Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADMA Biologics and other key companies, straight to your email.

About ADMA Biologics

ADMA Biologics (NASDAQ:ADMA), a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

View ADMA Biologics Profile

More Earnings Resources from MarketBeat